Important update: the meningitis B vaccine has since been given the go-ahead for consideration in the NHS vaccination schedule. Read about the role the meningitis B vaccination is likely to play in the NHS vaccination schedule.
The text below is the original Behind the Headlines article from January 23 2013, which explained that day's media stories in context.
Much of the media are reporting the news that a new meningitis B vaccine called Bexsero has been licensed by the European Commission. This means the vaccine should soon be available for use in the UK.
Meningitis B is a highly aggressive strain of bacterial meningitis that infects the protective membranes surrounding the brain and spinal cord. It is very serious and should be treated as a medical emergency. If the infection is left untreated, it can cause severe brain damage and infect the blood (septicaemia). In some cases, bacterial meningitis can be fatal.
The charity Meningitis UK estimates that there are 1,870 cases of meningitis B each year in the UK. Meningitis B is most common in children under five years old, and in particular in babies under the age of one.
Initial signs and symptoms of meningitis B in babies include:
For more information, read Signs and symptoms of serious illness in babies.
While there are effective vaccines against the other common strains of bacterial meningitis (A, C, W-135, Y3), until now there has been no vaccine against the B strain.
The development of a safe and effective meningitis B vaccine is the culmination of more than 20 years of research and represents a significant breakthrough in disease prevention.
The vaccine, Bexsero, is thought to provide 73% protection against meningitis B, which should significantly reduce the number of cases. The vaccine can be administered to infants aged two months or older either by itself, or in combination with other childhood vaccines.
The vaccine has been tested in clinical trials involving more than 8,000 people.
In infants, it was found to have similar levels of safety and tolerability as other routine childhood vaccines. The most commonly reported side effects were:
At the moment that is uncertain. The body that advises on vaccination policy – the Joint Committee on Vaccination and Immunisation (JCVI) – has not yet made any announcement.
The JCVI is due to meet in June 2013, although they are unlikely to make a decision until they have had time to consider the evidence of cost effectiveness and safety in greater detail. However, they may decide to "fast track" the decision.
The Bexsero vaccine is likely to be expensive and there is certainly no guarantee that the JCVI will rubber stamp a positive decision.
There are currently three possibilities: